Literature DB >> 26283451

Should we also evaluate SET together with CIP2A for the treatment with second-generation tyrosine kinase inhibitors in chronic myeloid leukemia?

I Cristóbal1, R Manso2, P González-Alonso2, F Rojo2, J García-Foncillas1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26283451     DOI： 10.1038/leu.2015.201

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  7 in total

1.  The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.

Authors:  Paolo Neviani; Ramasamy Santhanam; Rossana Trotta; Mario Notari; Bradley W Blaser; Shujun Liu; Hsiaoyin Mao; Ji Suk Chang; Annamaria Galietta; Ashwin Uttam; Denis C Roy; Mauro Valtieri; Rebecca Bruner-Klisovic; Michael A Caligiuri; Clara D Bloomfield; Guido Marcucci; Danilo Perrotti
Journal:  Cancer Cell       Date:  2005-11       Impact factor: 31.743

2.  Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.

Authors:  Mahnaz Janghorban; Amy S Farrell; Brittany L Allen-Petersen; Carl Pelz; Colin J Daniel; Jessica Oddo; Ellen M Langer; Dale J Christensen; Rosalie C Sears
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-09       Impact factor: 11.205

3.  FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.

Authors:  Paolo Neviani; Ramasamy Santhanam; Joshua J Oaks; Anna M Eiring; Mario Notari; Bradley W Blaser; Shujun Liu; Rossana Trotta; Natarajan Muthusamy; Carlo Gambacorti-Passerini; Brian J Druker; Jorge Cortes; Guido Marcucci; Ching-Shih Chen; Nicole M Verrills; Denis C Roy; Michael A Caligiuri; Clara D Bloomfield; John C Byrd; Danilo Perrotti
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

4.  Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients.

Authors:  C M Lucas; R J Harris; A K Holcroft; L J Scott; N Carmell; E McDonald; F Polydoros; R E Clark
Journal:  Leukemia       Date:  2015-03-13       Impact factor: 11.528

5.  Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A.

Authors:  Arelis Salas; Suriyan Ponnusamy; Can E Senkal; Marisa Meyers-Needham; Shanmugam Panneer Selvam; Sahar A Saddoughi; Elif Apohan; R David Sentelle; Charles Smith; Christopher R Gault; Lina M Obeid; Hesham M El-Shewy; Joshua Oaks; Ramasamy Santhanam; Guido Marcucci; Yusuf Baran; Sandeep Mahajan; Daniel Fernandes; Robert Stuart; Danilo Perrotti; Besim Ogretmen
Journal:  Blood       Date:  2011-04-28       Impact factor: 22.113

6.  Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression.

Authors:  Claire M Lucas; Robert J Harris; Athina Giannoudis; Mhairi Copland; Joseph R Slupsky; Richard E Clark
Journal:  Blood       Date:  2011-04-13       Impact factor: 22.113

7.  Discovery of a small molecule targeting SET-PP2A interaction to overcome BCR-ABLT315I mutation of chronic myeloid leukemia.

Authors:  Shuzhen Wang; Weiquan Xie; Duowei Wang; Zhigang Peng; Yan Zheng; Nan Liu; Wen Dai; Yang Wang; Zongqiang Wang; Yong Yang; Yijun Chen
Journal:  Oncotarget       Date:  2015-05-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.